Alterity Therapeutics has shown its Multiple System Atrophy drug ATH-434 has a potential market value of US$2.4 billion if approved. ... Read More The post StockTake: Alterity’s ATH434 shows US$2.4b ...
After menopause, women with MS show accelerated loss of volume in brain structures associated with memory, attention, and problem-solving.
As they explained in their case report in the Journal of Neurology and Neuroscience, ophthalmologic examination identified ...
While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
1 Clinical Research Center, Xuanwu Hospital Capital Medical University, Beijing, China 2 Department of Neurology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, ...
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
On August 24, 2006, our solar system lost a planet. It wasn't by cataclysmic destruction, but rather by the vote of the International Astronomical Union, which declared that Pluto, considered the ...
Health Policy and Health Economics researcher and a Honorary Researcher at the Centre for Health Services Studies, University of Kent Ethiopia has built a national emergency medical team and hosts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback